



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Initial application of: Wolfram and Letterio

Patent No. 6,756,215 B1

Issued: June 29, 2004

Application No. 10/017,372

Filed: October 19, 2001

Confirmation No. 6866

For: FUNCTIONALIZED TGF-BETA FUSION
PROTEINS

Examiner: Christopher J. Nichols, Ph.D.

Art Unit: 1647

Attorney Reference No. 4239-61302-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: ATTN: CERTIFICATE OF CORRECTION BRANCH, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s) Debra Gordon

Date Mailed February 3, 2006

ATTN: CERTIFICATE OF CORRECTION BRANCH
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:

- Request for Certificate of Correction;
- Certificate of Correction; and
- Check in the amount of \$100.00 in payment of the required fees.

The Director is hereby authorized to charge any additional fees that may be required, or credit overpayment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed. Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By: Debra Gordon
Debra A. Gordon, Ph.D.
Registration No. 54,128

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Wolfram and Letterio

Patent No. 6,756,215 *Bi*

Issued: June 29, 2004

Application No. 10/017,372

Filed: October 19, 2001

Confirmation No. 6866

For: FUNCTIONALIZED TGF-BETA FUSION
PROTEINS

Examiner: Christopher J. Nichols, Ph.D.

Art Unit: 1647

Attorney Reference No. 4239-61302-01

ATTN: CERTIFICATE OF CORRECTION BRANCH
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: ATTN: CERTIFICATE OF CORRECTION BRANCH, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Attorney or Agent
for Applicant(s) *Diana Rindfuss*

Date Mailed February 3, 2006

Certificate

FEB 13 2006

of Correction

REQUEST FOR CERTIFICATE OF CORRECTION

The following errors were noted in comparing the printed patent with the papers in the attorneys' files:

On Cover Page 1:

In the ninth publication under the heading OTHER PUBLICATIONS,
“Growth” should read -- Growth --

On Cover Page 2:

In the fourth publication under the heading OTHER PUBLICATIONS,
“Oda, et al. al.” should read -- Oda, et al. --

In the fourth publication under the heading OTHER PUBLICATIONS,
“Glycosylphosphatidylinosito-1-Anchored” should read -- Glycosylphosphatidylinositol-Anchored --

In the Specification:

Column 1, line 34, “el al.” should read -- et al. --

cofc

Column 3, line 8, "p11/12FLABb1" should read -- p11/12FLAGb1 --
Column 3, line 27, "11/12 FLAG" should read -- 11/12FLAG --
Column 3, line 53, " "anti-P-smad2." should read -- "anti-P-smad2." --
Column 3, line 66, "residues" should read -- (residues --
Column 4, line 5, "proved" should read -- probed --
Column 4, line 12, "cos-1" should read -- Cos1 --
Column 4, line 27, "smad 2" should read -- smad2 --
Column 4, line 63, "N FLAG- β 1" should read -- NFLAG- β 1 --
Column 6, line 66, "(removal)" should read -- ("removal") --
Column 9, line 31, "various known." should read -- various known assays.--

Column 9, line 43, "use" should read -- used --
Column 10, line 4, "Vecero" should read -- Vocero --
Column 13, line 39, "99%." should read -- 99% --
Column 14, line 61, "proteinsinclude" should read -- proteins include --
Column 15, line 3, "BMP4" should read -- BMP-4 --
Column 17, line 18, "fusions proteins" should read -- fusion proteins --
Column 17, line 22, "BMP3" should read -- BMP-3 --
Column 17, line 27, "BMP4" should read -- BMP-4 --
Column 18, line 57, "show" should read -- shown --
Column 18, line 60, "molecule" should read -- molecules --
Column 19, line 13, "BMP3" should read -- BMP-3 --
Column 19, line 17, "BMP4" should read -- BMP-4 --
Column 20, line 47, "BMP- β 16" should read -- BMP-16 --
Column 20, line 48, "BMP3" should read -- BMP-3 --
Column 20, line 50, "BMP- β 10 should read -- BMP-10 --
Column 22, line 3, "are" should read -- art --
Column 23, line 25, "a" should read -- as --
Column 23, line 18, "method" should read -- methods --

Column 24, line 28, "manufactures" should read -- manufacturers --
Column 26, line 30, "prolie" should read -- proline --
Column 26, line 37, "proteinencoding" should read -- protein-encoding --
Column 27, line 50, "malcic" should read -- maleic --
Column 28, line 20, "pharmacology Munson" should read

--Pharmacology, Munson --

Column 28, line 59, "an" should read -- a --
Column 29, line 8, "controls" should read -- control --
Column 29, line 35, "1996;" should read -- 1996). --
Column 29, line 48, "el al." should read -- et al. --
Column 29, line 62, "1999," should read -- 1999), --
Column 32, line 17, "et al. (In" should read -- et al., In --
Column 32, line 17, "Cloning." should read -- Cloning: --
Column 32, line 42, "TGF β " should read -- TGF- β --
Column 33, line 41, "159,2000" should read -- 159, 2000 --
Column 33, line 45, ".p275" should read -- , pp. 275 --
Column 34, line 43, "FLAG- β 1" should read -- TGF- β 1 --
Column 34, line 48, "ataagaattcgccgcgcttaatcgatcccaagtggcttgg" should
read -- ataagaattcgccgcgcttaatcgatcccaagtggcttgg --
Column 35, line 24, "cos 1" should read -- Cos1 --
Column 35, line 24, "serun" should read -- serum --
Column 35, line 33, "a Sandwich" should read -- Sandwich --
Column 35, line 51, "Cat" should read -- Cat. --
Column 35, line 54, "Cat" should read -- Cat. --
Column 35, line 65, "TGF- β 1is" should read -- TGF- β 1 is --
Column 35, line 65, "Secreted" should read -- Secreted. --
Column 36, line 3, "or" should read -- of --
Column 36, line 37, "smad 2" should read -- smad2 --
Column 36, line 47, "mm" should read -- mM --

Column 36, line 47, "Dr" should read -- DTT --

Column 36, line 50, "Cat" should read -- Cat. --

Column 36, line 62, "Activity" should read -- Activity. --

Column 36, line 64, "and" should read -- a --

Column 38, line 9, "TGFP" should read -- TGF- β --

Column 38, line 42, " \oplus " should read -- β --

Column 38, line 53, "(forward:" should read -- (forward) --

Column 41, line 38, "TGF β 1" should read -- TGF- β 1 --

Column 41, lines 38-39, "FLAG- and HA-tagged TGF- β 1 retain biological activity" should be the heading for the immediately following paragraph.

Column 41, line 67 through Column 42, line 2, "Specific detection of FLAG- and HA-tagged TGF- β 1 by sandwich ELISA (SELISA)" should be the heading for the immediately following paragraph.

Column 42, line 16, "Cos-1" should read -- Cos1 --

Column 42, lines 27-29, "FLAG-tagged TGF- β 1 can be detected by immunofluorescence confocal microscopy" should be the heading for the immediately following paragraph.

Column 42, line 32, "Cos-1" should read -- Cos1 --

Column 42, line 56, "Mv1lu" should read -- Mv1Lu --

Column 44, line 23, "51" should read -- β 1 --

Column 44, Table 2, "(NOs: 16 & 17) (1-404)"

should read -- (NOs: 16 & 17) (1-404)³ --

Column 44, Table 2, "³residues" should read -- ³Residues --

In the Claims:

Column 122, line 37, "M-nature" should read -- mature --

Column 122, line 40, "for" should read -- of --

Column 122, line 51, "lag" should read -- tag --

Column 122, line 52, "Tal" should read -- Tat --

Column 123, line 1, "eukariotic" should read -- eukaryotic --

Allowed claim 61 (renumbered 25) was omitted and should be added after Column 124, line 3 as follows:

25. The fusion protein of claim 2, where the protein comprises the amino acid sequence as in the mature portion of SEQ ID NO: 9, 11, 13, 15, 33 or 39.

The preceding corrections remedy mistakes of a typographical nature and/or minor character. The Certificate of Correction is enclosed to make formal notice of the errors in the referenced patent. Pursuant to 37 CFR 1.20(a), a check in the amount of \$100.00 accompanies this filing.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By: Debra Gordon
Debra A. Gordon, Ph.D.
Registration No. 54,128

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

FEB 18 2006

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,756,215 B1

DATED : June 29, 2004

INVENTOR(S) : Wolfram and Letterio

It is certified that errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On Cover Page 1:

In the ninth publication under the heading OTHER PUBLICATIONS, "Growt" should read -- Growth --

On Cover Page 2:

In the fourth publication under the heading OTHER PUBLICATIONS, "Oda, et al. al." should read -- Oda, et al. --

In the fourth publication under the heading OTHER PUBLICATIONS, "Glycosylphosphatidylinosito-l-Anchored" should read -- Glycosylphosphatidylinositol -Anchored --

In the Specification:

Column 1, line 34, "el al." should read -- et al. --

Column 3, line 8, "p11/12FLABb1" should read -- p11/12FLAGb1 --

Column 3, line 27, "11/12 FLAG" should read --11/12

FLAG--

Column 3, line 53, " "anti-P-smad2. " should read -- "anti-P-smad2." --

Column 3, line 66, "residues" should read -- (residues --

Column 4, line 5, "proved" should read -- probed --

Column 4, line 12, "cos-1" should read -- Cos1 --

Column 4, line 27, "smad 2" should read -- smad2 --

Column 4, line 63, "N FLAG- β 1" should read -- NFLAG- β 1 --

Column 6, line 66, "(removal)" should read -- ("removal") --

Column 9, line 31, "various known." should read -- various known assays.--

Column 9, line 43, "use" should read -- used --

Column 10, line 4, "Vecero" should read -- Vocero --

Column 13, line 39, "99%." should read -- 99% --

Column 14, line 61, "proteinsinclude" should read -- proteins include --

Column 15, line 3, "BMP4" should read -- BMP-4 --

Column 17, line 18, "fusions proteins" should read -- fusion proteins --

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. US 6,756,215

No. of add'l copies _____
(@ .30 per page)

Page 1 of 4

FEB 13 2006

Column 17, line 22, "BMP3" should read -- BMP-3 --
Column 17, line 27, "BMP4" should read -- BMP-4 --
Column 18, line 57, "show" should read -- shown --
Column 18, line 60, "molecule" should read -- molecules --
Column 19, line 13, "BMP3" should read -- BMP-3 --
Column 19, line 17, "BMP4" should read -- BMP-4 --
Column 20, line 47, "BMP-β16" should read -- BMP-16 --
Column 20, line 48, "BMP3" should read -- BMP-3 --
Column 20, line 50, "BMP-β10 should read -- BMP-10 --
Column 22, line 3, "are" should read -- art --
Column 23, line 25, "a" should read -- as --
Column 23, line 18, "method" should read -- methods --
Column 24, line 28, "manufactures" should read -- manufacturers --
Column 26, line 30, "prolie" should read -- proline --
Column 26, line 37, "proteinencoding" should read -- protein-encoding --
Column 27, line 50, "malcic" should read -- maleic --
Column 28, line 20, "pharmacology Munson" should read
--Pharmacology, Munson --
Column 28, line 59, "an" should read -- a --
Column 29, line 8, "controls" should read -- control --
Column 29, line 35, "1996;" should read -- 1996). --
Column 29, line 48, "el al." should read -- et al. --
Column 29, line 62, "1999," should read -- 1999), --
Column 32, line 17, "et al. (In" should read -- et al., In --
Column 32, line 17, "Cloning." should read -- Cloning: --
Column 32, line 42, "TGFβ" should read -- TGF-β --
Column 33, line 41, "159,2000" should read -- 159, 2000 --
Column 33, line 45, ",p275" should read -- , pp. 275 --
Column 34, line 43, "FLAG-β1" should read -- TGF-β1 --
Column 34, line 48, "ataagaattgcggccgtaatcgatccaaagtggcttgg" should read --
ataagaattgcggccgttaatcgatccaaagtggcttgg --
Column 35, line 24, "cos 1" should read -- Cos1 --
Column 35, line 24, "serun" should read -- serum --
Column 35, line 33, "a Sandwich" should read -- Sandwich --
Column 35, line 51, "Cat" should read -- Cat. --
Column 35, line 54, "Cat" should read -- Cat. --

MAILING ADDRESS OF SENDER:

Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. US 6,756,215 *B1*
No. of add'l copies _____
(@ .30 per page)

Column 35, line 65, "TGF- β 1is" should read -- TGF- β 1 is --
Column 35, line 65, "Secreted" should read -- Secreted. --
Column 36, line 3, "or" should read -- of --
Column 36, line 37, "smad 2" should read -- smad2 --
Column 36, line 47, "mm" should read -- mM --
Column 36, line 47, "Dr" should read -- DTT --
Column 36, line 50, "Cat" should read -- Cat. --
Column 36, line 62, "Activity" should read -- Activity. --
Column 36, line 64, "and" should read -- a --
Column 38, line 9, "TGFP" should read -- TGF- β --

Column 38, line 42, " \oplus " should read -- β --
Column 38, line 53, "(forward:" should read -- (forward) --
Column 41, line 38, "TGF β 1" should read -- TGF- β 1 --
Column 41, lines 38-39, "FLAG- and HA-tagged TGF- β 1 retain biological activity"
should be the heading for the immediately following paragraph.
Column 41, line 67 through Column 42, line 2, "Specific detection of FLAG- and HA-
tagged TGF- β 1 by sandwich ELISA (SELISA)" should be the heading for the immediately
following paragraph.
Column 42, line 16, "Cos-1" should read -- Cos1 --
Column 42, lines 27-29, "FLAG-tagged TGF- β 1 can be detected by immunofluorescence
confocal microscopy" should be the heading for the immediately following paragraph.
Column 42, line 32, "Cos-1" should read -- Cos1 --
Column 42, line 56, "Mv1lu" should read -- Mv1Lu --
Column 44, line 23, "51" should read -- β 1 --
Column 44, Table 2, "(NOs: 16 & 17) (1-404)"
should read -- (NOs: 16 & 17)¹ (1-404)³ --
Column 44, Table 2, "³residues" should read -- ³Residues --

In the Claims:

Column 122, line 37, "M-nature" should read -- mature --
Column 122, line 40, "for" should read -- of --
Column 122, line 51, "lag" should read -- tag --
Column 122, line 52, "Tal" should read -- Tat --
Column 123, line 1, "eukariotic" should read -- eukaryotic --

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. US 6,756,215 β
No. of add'l copies _____
(@ .30 per page)

Allowed claim 61 (renumbered 25) was omitted and should be added after Column 124, line 3 as follows:

25. The fusion protein of claim 2, where the protein comprises the amino acid sequence as in the mature portion of SEQ ID NO: 9, 11, 13, 15, 33 or 39.

MAILING ADDRESS OF SENDER:
Klarquist Sparkman, LLP
One World Trade Center, Suite 1600
121 SW Salmon Street
Portland, Oregon 97204

PATENT NO. US 6,756,215 B1
No. of add'l copies _____
(@ .30 per page)

Page 4 of 4

FEB 13 2006